论文部分内容阅读
目的探讨内分泌治疗联合唑来膦酸治疗前列腺癌骨转移的应用价值。方法入选20例前列腺癌骨转移患者,给予醋酸戈舍瑞林3.6mg皮下注射,第1天,氟他胺250mg口服,2次/d,唑来膦酸4mg静脉注射,第1天,每四周为一周期,每例接受治疗3～8个周期不等。结果本组病例随访6～54周,中位40周,治疗后患者PSA明显下降、Karnofsky Score评分明显升高。18例患者骨痛缓解,中位生存期大于12个月,不良反应可耐受。结论内分泌治疗联合唑来膦酸治疗前列腺癌骨转移有较好疗效,不良反应轻。
Objective To investigate the value of endocrine therapy combined with zoledronic acid in treatment of bone metastasis of prostate cancer. Methods Twenty patients with prostate cancer with bone metastasis were injected with 3.6 mg of goserelin acetate subcutaneously. On the first day, 250 mg of flutamide was administered orally, twice daily and 4 mg of zoledronic acid intravenously. On day one, every four weeks For a cycle, each treatment received 3 to 8 cycles. Results The patients were followed up for 6 to 54 weeks with a median of 40 weeks. After treatment, the PSA was significantly decreased and Karnofsky Score was significantly higher. Eighteen patients had relief of bone pain with a median survival of more than 12 months, with adverse reactions tolerated. Conclusions Endocrine therapy combined with zoledronic acid has good curative effect on bone metastasis of prostate cancer with mild adverse reactions.